Cost of Revenue
Total Cost of Revenue
Pfizer Total Cost of Revenue decreased by 32.7% to $3.55B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 24.7%, from $2.85B to $3.55B. Over 4 years (FY 2021 to FY 2025), Total Cost of Revenue shows a downward trend with a -15.0% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementIncome Statement
SectionCost of Revenue
CategoryProfitability
SignalLower is better
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026May 5, 2026
How to read this metric
An increase relative to revenue suggests rising production costs or margin compression, while a decrease suggests improved operational efficiency.
Detailed definition
Total cost of revenue includes the direct costs attributable to the production of goods or the delivery of services sold...
Peer comparison
Varies by industry; for medical device manufacturers, this includes significant manufacturing and supply chain costs.
Metric ID:
total_cost_of_revenueHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.00B | $9.93B | $9.74B | $9.98B | $8.65B | $6.06B | $9.65B | $4.89B | $3.24B | $9.27B | $7.56B | $3.38B | $3.30B | $5.26B | $5.91B | $2.85B | $3.78B | $4.17B | $5.27B | $3.55B |
| QoQ Change | — | +42.0% | -2.0% | +2.5% | -13.4% | -29.9% | +59.1% | -49.4% | -33.7% | +186.3% | -18.4% | -55.3% | -2.3% | +59.5% | +12.3% | -51.9% | +32.8% | +10.4% | +26.4% | -32.7% |
| YoY Change | — | — | — | — | +23.6% | -39.0% | -0.9% | -51.1% | -62.6% | +52.9% | -21.6% | -30.8% | +1.9% | -43.2% | -21.9% | -15.8% | +14.5% | -20.7% | -10.8% | +24.7% |
Range$2.85B – $9.98B
CAGR-13.3%
Avg YoY Growth-12.5%
Median YoY Growth-18.3%
Business Segments
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Biopharma | $2.41B | $4.63B | $5.31B | $2.31B | $3.08B | $3.53B | $4.59B | $3.03B |
| Total | $3.30B | $5.26B | $5.91B | $2.85B | $3.78B | $4.17B | $5.27B | $3.55B |
Total Cost of Revenue at Other Companies
Frequently Asked Questions
- What is Pfizer's total cost of revenue?
- Pfizer (PFE) reported total cost of revenue of $3.55B in Q1 2026.
- How has Pfizer's total cost of revenue changed year-over-year?
- Pfizer's total cost of revenue increased by 24.7% year-over-year, from $2.85B to $3.55B.
- What is the long-term trend for Pfizer's total cost of revenue?
- Over 4 years (2021 to 2025), Pfizer's total cost of revenue has grown at a -15.0% compound annual growth rate (CAGR), from $30.82B to $16.07B.
- What does total cost of revenue mean?
- The direct costs incurred to produce the goods or services that a company sold during a specific period.